-
2025-522855-25-00
5
Carcinoma, Transitional Cell
-
2025-523285-25-00
5
Relapsed or Refractory Multiple Myeloma
-
2025-521884-12-00
5
2026-03-19
First line triple-negative breast cancer (TNBC)
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2025-521276-59-00
5
2025-12-16
Autosomal dominant polycystic kidney disease (ADPKD)
-
2022-500461-28-06
5
2022-09-15
High-Risk Metastatic Hormone-Sensitive Prostate Cancer
-
2024-516544-26-00
4
2026-03-30
acute ischemic stroke
-
2025-521762-99-00
5
2026-03-09
acute ischemic stroke
-
2024-511362-37-00
5
2026-02-18
Non squamous non-small cell lung cancer (NSCLC)
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2025-521627-78-00
5
2026-01-28
Neoplasms, Lung
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2023-507879-21-00
4
2026-01-19
AML and MDS undergoing allogeneic Transplantation
-
2024-513586-39-00
5
2025-12-10
Prostate Cancer
-
2025-520927-26-00
5
2025-11-24
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2023-510490-34-00
4
2025-09-29
Patients with functionally resectable pancreatic ductal adenocarcinoma
-
2023-509630-19-00
5
2025-07-31
Esophageal Squamous Cell Carcinoma (ESCC)
-
2024-517423-40-00
5
2025-06-23
Metastatic Castration-Resistant Prostate Cancer
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2023-505077-32-00
5
2025-01-28
Locally-advanced or metastatic non-squamous non-small cell lung cancer
-
2024-513420-41-00
10
2025-01-09
prematurity in neonates
-
2023-510150-17-00
4
2024-12-11
Active, refractory systemic lupus erythematosus (SLE), and active, re
-
2023-510380-34-00
4
2024-12-10
Diffuse cutaneous systemic sclerosis (dcSSc)
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation